QIAGEN N.V.’s QGEN fourth-quarter performance was driven by solid potential in molecular diagnostics. The company continues to progress with its test menu expansion, building a solid foundation to ...

Qiagen alleges that BioMérieux infringes a European patent that protects the company's QuantiFeron interferon-gamma release assay technology for latent TB detection.

QIAGEN has filed a lawsuit against bioMérieux in the German Unified Patent Court to protect its QuantiFERON technology, specifically its Europea ...

Qiagen (QGEN) announced that it has filed a complaint against bioMerieux for patent infringement. The complaint, filed in the Local Division of ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A.